Pseudomyxoma peritonei epidemiology and demographics

	Pseudomyxoma peritonei Microchapters
Home
Patient Information
Overview
Historical Perspective
Pathophysiology
Causes
Differentiating Pseudomyxoma peritonei from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Pseudomyxoma peritonei epidemiology and demographics On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Pseudomyxoma peritonei epidemiology and demographics All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Pseudomyxoma peritonei epidemiology and demographics
CDC on Pseudomyxoma peritonei epidemiology and demographics
Pseudomyxoma peritonei epidemiology and demographics in the news
Blogs on Pseudomyxoma peritonei epidemiology and demographics
Directions to Hospitals Treating Pseudomyxoma peritonei
Risk calculators and risk factors for Pseudomyxoma peritonei epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]

Overview

The overall incidence of pseudomyxoma peritonei is 0.1 cases per 100,000 people per year. ^[1]
Pseudomyxoma peritonei is slightly more common in females than males
The female to male ratio is 11:9.
The median age at presentation is typically about 50 years of age.

↑ Baratti D, Kusamura S, Nonaka D, Langer M, Andreola S, Favaro M, Gavazzi C, Laterza B, Deraco M (February 2008). "Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC)". Ann. Surg. Oncol. 15 (2): 526–34. doi:10.1245/s10434-007-9691-2. PMID 18043976.